Similar articles

• Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.

  Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB; American Thoracic Society. Feldman RB, et al. Arch Intern Med. 2003 Jul 28;163(14):1718-26. doi: 10.1001/archinte.163.14.1718. Arch Intern Med. 2003. PMID: 12885688
• Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?

  Sánchez F, Mensa J, Martínez JA, García E, Marco F, González J, Marcos MA, Soriano A, Torres A. Sánchez F, et al. Clin Infect Dis. 2003 May 15;36(10):1239-45. doi: 10.1086/374846. Epub 2003 May 6. Clin Infect Dis. 2003. PMID: 12746768 Clinical Trial.
• Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

  Amsden GW. Amsden GW. J Antimicrob Chemother. 2005 Jan;55(1):10-21. doi: 10.1093/jac/dkh519. Epub 2004 Dec 8. J Antimicrob Chemother. 2005. PMID: 15590715 Review.
• Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

  Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA. Ye X, et al. Clin Ther. 2008 Feb;30(2):358-71. doi: 10.1016/j.clinthera.2008.01.023. Clin Ther. 2008. PMID: 18343274
• Clinical implications of macrolide resistance in community-acquired respiratory tract infections.

  Hoban DJ, Zhanel GG. Hoban DJ, et al. Expert Rev Anti Infect Ther. 2006 Dec;4(6):973-80. doi: 10.1586/14787210.4.6.973. Expert Rev Anti Infect Ther. 2006. PMID: 17181414 Review.